| scholarly article | Q13442814 |
| P2093 | author name string | Benjamin E Rich | |
| Khalid Shah | |||
| Daniel W Stuckey | |||
| Nihal Karakas | |||
| Shawn D Hingtgen | |||
| P2860 | cites work | Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter | Q24671715 |
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma | Q30431291 | ||
| Advances in brain tumor surgery | Q31134396 | ||
| A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival | Q34108339 | ||
| Isolation of two human tumor epithelial cell lines from solid breast carcinomas | Q34160332 | ||
| Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model | Q34198939 | ||
| The use of neural stem cells in cancer gene therapy: predicting the path to the clinic | Q34217778 | ||
| Review of epidermal growth factor receptor biology | Q34320636 | ||
| Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. | Q34359268 | ||
| Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies | Q34567940 | ||
| Engineered antibody fragments and the rise of single domains | Q34650980 | ||
| Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer | Q34988874 | ||
| NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin, | Q35081775 | ||
| A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer | Q35230663 | ||
| Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. | Q35812718 | ||
| Studies on the mode of action of diphtheria toxin. VII. Toxin-stimulated hydrolysis of nicotinamide adenine dinucleotide in mammalian cell extracts | Q36269506 | ||
| Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. | Q36339837 | ||
| Immunotoxins in the treatment of hematologic malignancies | Q36638455 | ||
| BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. | Q36692818 | ||
| Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas | Q36695971 | ||
| Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display | Q36837485 | ||
| Stem and progenitor cell-mediated tumor selective gene therapy | Q37120161 | ||
| Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare | Q37122166 | ||
| Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Q37140126 | ||
| Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia | Q37242280 | ||
| Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors | Q37447217 | ||
| Oncogenic EGFR signaling networks in glioma | Q37593841 | ||
| Understanding high grade glioma: molecular mechanism, therapy and comprehensive management | Q38075981 | ||
| Stem cell-based therapies for cancer treatment: separating hope from hype | Q38245163 | ||
| A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing | Q38326533 | ||
| A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models | Q39630653 | ||
| Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model | Q39988659 | ||
| Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies | Q40177093 | ||
| Bioactive IL7-diphtheria fusion toxin secreted by mammalian cells | Q40442648 | ||
| Diphtheria Toxin−Epidermal Growth Factor Fusion Protein and Pseudomonas Exotoxin−Interleukin 13 Fusion Protein Exert Synergistic Toxicity against Human Glioblastoma Multiforme Cells | Q40615599 | ||
| Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies | Q40623388 | ||
| Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. | Q40860001 | ||
| Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. | Q40899057 | ||
| Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer | Q40991516 | ||
| Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma | Q42631907 | ||
| Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. | Q43115465 | ||
| Interleukin-13 receptor as a unique target for anti-glioblastoma therapy | Q43567315 | ||
| Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario | Q44763875 | ||
| Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy | Q46825509 | ||
| Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses | Q48070476 | ||
| Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors | Q48447313 | ||
| Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. | Q53403935 | ||
| Highly frequent single amino acid substitution in mammalian elongation factor 2 (EF-2) results in expression of resistance to EF-2-ADP-ribosylating toxins. | Q54400378 | ||
| Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. | Q54768075 | ||
| Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. | Q55480258 | ||
| One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell | Q67390807 | ||
| A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4 | Q71921204 | ||
| Responses in refractory hairy cell leukemia to a recombinant immunotoxin | Q73160386 | ||
| Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies | Q80977096 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P921 | main subject | brain tumor | Q233309 |
| P304 | page(s) | 589-600 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Stem Cells | Q15724411 |
| P1476 | title | Engineering toxin-resistant therapeutic stem cells to treat brain tumors | |
| P478 | volume | 33 |
| Q38944271 | Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. |
| Q57640952 | Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection |
| Q50075766 | Mesenchymal Stromal/Stem Cells: A New Era in the Cell-Based Targeted Gene Therapy of Cancer. |
| Q45858463 | Mesenchymal stem cell: a new horizon in cancer gene therapy |
| Q38627347 | Multifunctional receptor-targeting antibodies for cancer therapy |
| Q33704489 | Neural stem cell therapy for cancer |
| Q38855638 | Stem cell-based therapies for tumors in the brain: are we there yet? |
| Q39285733 | Therapeutic application of multipotent stem cells |
| Q48275610 | Toxin-secreting implantable therapeutic stem cells |
| Q50083504 | Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas. |
| Q37589818 | Vitamin B12: a tunable, long wavelength, light-responsive platform for launching therapeutic agents |
Search more.